培训课件--血瘀证和活血化瘀治疗临床研究.ppt

Thanks for Attention 谢谢大家 * * * Progress of RS Study Restenosis (RS) is still the major limitation of the long-term success of coronary intervention treatment No ideal prophylactic measure so far although numerous clinical trials have been done Stents have certain effect with RS rate still between 20% and 30% Coating stents showed wonderful prospect, but the reported results were inconsistent, and the expensive price limited its application in China 再狭窄(RS)研究进展 再狭窄仍然是限制冠状动脉介入治疗远期疗效的主要因素 虽然国际上进行了大量干预再狭窄的临床试验，但目前还没有找到理想的治疗手段 支架植入术具有一定的效果，但再狭窄发生率仍然在20%～30%之间。 药物涂层支架显是有良好的前景，但研究结果报道不一，其昂贵的价格也限制了其在国内的推广应用 血府逐瘀汤Xue Fu Zhu Yu Tang Wang Qing-Ren(1768-1831AD) of Qing Dynasty 清. 王清任 The Typical Recipe of Activating Blood Circulation and Removing Stasis 活血化瘀代表方 Medicinal Roles Sovereign (君) – Semen Persicae (桃仁)，Flos Carthami (红花) , Radix Angelicae (当归)； Minister (臣) –Padix Raeoniae Rubra (赤芍)，Rhizoma Ligustici Chuanxiong (川芎)，Radix Rhemanniae (生地)； Assistant (佐) –Radix Achyranthis Bidentatae (牛膝)，Radix Bupleuri (柴胡), Fructus Aurantii (枳壳)，Radix Platycodi (桔梗)； Envoy (使) –Radix Glycyrrhizae (甘草). 介入治疗后再狭窄 Restenosis Post PTCA/Stent 中医“血瘀证” BSS 经典活血化瘀方 血府逐瘀制剂 XFZYT 简化方药 Modified XFZYT 精制血府胶囊 Concentrated XFZYT 芎芍胶囊 XS Capsule Effective components A B C D E F A：Model B：Probucol C：Xue Fu Zhu Yu Preparation D：Low-dose XS E：Large-dose XS F：Normal Our previous Experimental Study (China Minipig, VG×50) 4 weeks after balloon injury of coronary artery 我们既往 实验研究 (中国小型猪, VG×50) 冠状动脉球囊损伤后4周 A：对照组 B：普罗布考组 C：血管通组 D：芎芍小组 E：芎芍大组 F：正常对照 RS “Blood Stasis” Syndrome Xue Fu Zhu Yu Preparation Simplify and Optimize Prescription Xiongshao Capsule SMC proliferation PLT aggregation Thrombosis Vascular remodeling The Course of Our Study Effective Active parts from Rhizoma chuanxiong and Radix Paeoniae rubra EBM? RCT? Pilot study showed its effectiveness 临床研究进程 再狭窄 中医“血瘀证” 经典活血化瘀方 血府逐瘀制剂 有 效 精简优化方药 芎芍胶囊 SMC增殖